الفهرس 
IntroductionOnly 14 pages are availabe for public view
 |  | from | 106 |  |  |
| | | from | 106 | | |
Abstract
Sodium-glucose cotransporter 2 inhibitors (SGLT2i) represent a recent class
of oral hypoglycemic agents available to treat patients with type 2 diabetes mellitus
in addition, SGLT2i have been shown to reduce cardiovascular death risk and HF
worsening in patients with HF with reduced ejection fraction (HFrEF) and HF with
preserved ejection fraction (HFpEF), regardless of diabetes status.
A post-infectious complication of rheumatic fever, rheumatic valvular heart
disease caused by an atypical immunological response to streptococcal pharyngitis,
which in turn causes valvular damage that is considered a major cardiac condition
in many underdeveloped nations, including Egypt, and mitral regurgitation (MR) is
considered as a common valve lesion.
We enrolled 150 patients with severe rheumatic mitral regurgitation and
preserved LV function (LV EF > 60%) in A prospective cohort study; half of them
received Dapagliflozin and the others did not to assess the effect of dapagliflozin in
patients with severe mitral regurgitation and preserved LV function
The main findings is there were significant improvement in patients who
received dapagliflozin (cases) compared to those who did not (control) with
median score of KCCQ for cases was (71.5) compared to (62.6) for control group,
p value < 0.001 ) with no statistically significant difference between the two
groups regarding basal GLS and GLS after 3 months of follow up.